Entos Pharmaceuticals

John Lewis, Ph.D., CEO

April 9 | 2:15pm | Salone dei Cavalieri, Section 2

Edmonton, Alberta, Canada


Entos Pharmaceuticals Inc. is a clinical-stage genetic medicines company founded in 2016.  Our proprietary Fusogenix™ Proteo-Lipid Vehicle™ (PLV™) platform, enables precision non-viral, re-dosable delivery of all nucleic acids payloads (DNA, RNA, or combinations), ushering in the new era of genetic medicine.  The Fusogenix platform combines the best attributes of current viral and nonviral delivery technology that allows for delivery of all nucleic acid modalities including gene editing tools. The Fusogenix platform can target specific tissues, including extra-hepatic targets with precision, avoiding the liver altogether if desired. Entos is leveraging its groundbreaking Fusogenix platform to solve the delivery problem holding back the advancement of genetic medicines. Entos is developing these therapies through its internal pipeline and through partnerships with other biotech/pharma companies.


By using this website you agree to accept our Privacy Policy and Terms & Conditions